LQDA · Liquidia Corporation

Current Thesis

The setup that was coiling into a binary last month just got its worst tail cut, and price responded. On 2026-06-04 the Supreme Court ruled unanimously (Justice Jackson) for the generic side in Hikma v. Amarin, raising the bar for induced-infringement / "skinny-label" claims. HC Wainwright (PT raised $67→$75, 2026-06-05) read it directly onto LQDA: it "eliminates a worst-case scenario of a potential forced NDA withdrawal," and its patent counsel now sees monetary damages as more likely than a full injunction out of the UTHR '327 trial that begins 2026-06-23 (D. Del., 1:23-cv-00975). LQDA gapped +17.92% to $65.77 on 2026-06-04, a fresh 52-week high. So the narrative is now accelerating on two legs at once the YUTREPIA commercial ramp (Q1'26 net sales $129.9M, +44% QoQ, profitable) and a structural de-risking of the legal overhang. Binary, but the distribution of outcomes just shifted toward the bull.

Bull Case

• Legal tail cut, not just deferred the 2026-06-04 SCOTUS skinny-label ruling makes a forced YUTREPIA withdrawal far harder to obtain; the live question narrows toward damages vs. injunction rather than product survival. Full FDA approval (2025-05-23) stays intact regardless of the trial.
• Ramp still accelerating Q1'26 (call 2026-05-11) YUTREPIA net sales $129.9M, +44% sequential off Q4'25's $90.1M; total revenue $132.9M beat $116.7M consensus; EPS $0.52 vs $0.41; net income $52.9M; adj EBITDA $71.2M. Cash ~$223M, self-funded.
• Share compounding ~23% of the inhaled-prostacyclin segment; ~4,500 cumulative scripts / ~3,750 patients since the June 2025 launch; management reiterates line of sight to $1B net revenue in 2027.
• Street chasing, PTs rising again post-ruling cluster: HC Wainwright $75 (Street high), Needham $70, Wells Fargo $62, Jefferies $60, BTIG $59; consensus ~$66, rating Strong Buy.
• '327 is narrow the patent covers PH-ILD only, not PAH; LQDA also counter-sued UTHR on the '494 dosing-regimen patent, giving it offensive leverage.

Bear Case

• Binary still binary the '327 trial begins 2026-06-23; an injunction outcome (even if less likely post-Hikma) still disrupts the single revenue engine, and appeals follow either way. Entering right before it is event exposure, not edge.
• Stretched after a one-day +18% spike price at a 52-week high (range $11.85–$66.24), already through the ~$66 consensus PT, with only the lone $75 target above. The easy repricing is largely done (+286% YoY).
• Single-product concentration YUTREPIA is ~98% of revenue; any commercial or legal stumble hits the whole thesis at once.
• Entrenched, well-capitalized rival UTHR's Tyvaso DPI is standard of care; LQDA's gains are zero-sum against a competitor still litigating and defending the channel.
• Premium on trailing math ~$5.5B market cap, trailing P/E ~253 (forward ~15 only if the $1B/2027 path lands); the 2027 trajectory has to actually arrive.

Setup & Price Structure

• Last close $61.85 (2026-06-05, −1.1%), after-hours ~$64; the 2026-06-04 close was $65.77 on a +17.92% session. New 52-week high $66.24.
• The chart broke its prior cage: three weeks of tight $54–57 consolidation after the +15.7% Q1 earnings pop (2026-05-11), then the SCOTUS-ruling gap on 2026-06-04 cleared it decisively. That $54–57 shelf is now the breakout/support reference; the older $48–50 base is stale.
• Momentum is hot but extended a +18% one-day candle into a 52-week high pushes short-term RSI up; the −1.1% on 2026-06-05 is a normal first digest, not distribution.
• Beginner-trap read: this is a chase-the-spike-into-a-binary zone. The spike was driven by genuine tail-risk removal, not retail froth, so it is not peak-mania but a fresh entry at $62–64 pays up the day after the move and ahead of the 2026-06-23 trial. Not averaging-down territory; not stretched 50% above MA either.
• Theme state: ACCELERATING on both commercial and legal legs, gated by the June 23 event.

Catalyst Calendar (next 30 days)

• 2026-06-23 UTHR '327 patent trial begins (D. Del., 1:23-cv-00975). The remaining binary. Post-Hikma, the realistic bear outcome is damages rather than a withdrawal/injunction; a clean LQDA win removes the last overhang.
• Ongoing appeal/ruling read-through from Hikma v. Amarin (decided 2026-06-04). Watch for follow-on analyst notes re-rating the injunction probability; HC Wainwright already moved (2026-06-05, PT $75).
• ~early Aug 2026 (est.) Q2'26 print. Outside the 30-day window but the next commercial-ramp checkpoint; thesis is not earnings-driven, so treat the print as confirmation, not the catalyst.

What Would Change Our Mind

• A '327 trial ruling (post 2026-06-23) granting UTHR a permanent injunction rather than monetary damages the de-risking thesis would be wrong and the single revenue engine is impaired.
• A weekly close back below the $54–57 breakout shelf the June-4 breakout failed and price fell back into the old range, signaling the legal re-rate was faded.
• Q2'26 YUTREPIA net sales <$130M a sequential decline breaks the ramp narrative regardless of the legal outcome.
• Theme flip to SATURATED mainstream/retail saturation with price stalling below the $75 high PT and PT raises drying up.

Correlation Notes

• Structurally inverse to UTHR (Tyvaso franchise): the same trial and the same Hikma read-through that help LQDA pressure UTHR's exclusivity. Holding both long as a "PAH basket" cancels the edge these are two sides of one trade.
• Skinny-label read-through: the Hikma v. Amarin precedent is a sector event for generic/505(b)(2) names litigating method-of-use patents; LQDA is among the cleanest single-name expressions of it right now.
• Idiosyncratic, low beta (~0.59) moves on its own catalysts (ramp prints, court dates, the SCOTUS ruling), not the index; a tape-wide risk-off does little to the thesis, while a single adverse '327 line moves it 15–20% in a session.